KOE · 115450.KQ
HLB Therapeutics Co.,Ltd.
₩2,530-₩30 (-1.17%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.18% below the high.
Loading market information…
KOE · 084990.KQ · KRW
Stock price, earnings
Quote as of Oct 30, 2026, 04:35 AM UTC. Cached market data; not a live quote.
One-year closing-price history · KRW. Historical prices are not a forecast.
Helixmith Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 62.65% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Helixmith Co., Ltd’s next earnings report is currently expected on Nov 18, 2026, with estimated earnings per share of ₩446. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Helixmith Co., Ltd’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Helixmith Co., Ltd is a biotechnology enterprise focused on discovering and advancing novel biopharmaceutical solutions for human diseases. The company maintains a comprehensive pipeline of innovative biologics and herbal therapies, addressing therapeutic areas like cardiovascular ailments, cancer, and immune system disorders. Its clinical research activities are actively conducted across the United States, South Korea, and China. A cornerstone of its product portfolio is VM202, a groundbreaking DNA-based drug designed for treating both cardiovascular and neurological conditions. Additionally, Helixmith's developmental compounds include VM206, a therapeutic vaccine targeting HER2/neu positive breast or ovarian cancer, and VM501, a re-engineered variant of interleukin 11 aimed at alleviating chemotherapy-induced thrombocytopenia. Its ongoing clinical trials encompass VM202-DPN, VM202-PAD, VM501, VM202-ALS, VM202-CAD, and VM206. Founded in 1996, the company adopted the name Helixmith Co., Ltd in April 2019, transitioning from its former identity as ViroMed Co., Ltd. The organization's main office is located in Seoul, South Korea.
Latest available per-share figures in KRW. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| ₩930.47M-46.73% vs estimate |
| Q4 2024 | Feb 12, 2025 | -₩43 | ₩1.63B-6.52% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | -₩82+79.66% vs estimate | ₩1.8B+239,659.97% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₩2,530-₩30 (-1.17%)
HLB Therapeutics Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.18% below the high.
₩5,810-₩110 (-1.86%)
JETEMA, Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 48.49% below the high.
₩6,900-₩80 (-1.15%)
Bioneer Corporation’s quoted price sits in the lower half of its reported 52-week range, 61.56% below the high.
₩5,260-₩90 (-1.68%)
EASY BIO,Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.55% below the high.
₩13,470-₩610 (-4.33%)
Anterogen.Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 78.2% below the high.
₩10,850-₩100 (-0.91%)
Macrogen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.09% below the high.
₩2,985+₩15 (+0.51%)
MedPacto, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.49% below the high.
₩2,165₩0 (0.0%)
Genexine, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.09% below the high.
